Marena Trinidad
BioMarin Pharmaceutical
32 Papers
5 Citations
Marena Trinidad is an academic researcher from BioMarin Pharmaceutical. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Connor A. Tsuchida,Nadav Brandes,Raymund Bueno,Marena Trinidad,Thomas Mazumder,Bingfei Yu,Byungjin Hwang,Christopher Chang,Jamin Liu,Yang Sun,Caitlin R. Hopkins,Kevin R. Parker,Yanyan Qi,Laura Hofman,Ansuman T. Satpathy,Edward A. Stadtmauer,Jamie H.D. Cate,Justin Eyquem,Joseph A. Fraietta,Carl H June,Howard Y. Chang,Chun Jimmie Ye,Jennifer A. Doudna +22 more
TL;DR: A modified cell manufacturing process employed in the first-in-human clinical trial of Cas9-engineered T cells (NCT03399448), reduced chromosome loss while largely preserving genome editing efficacy, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.
79
In vivo human T cell engineering with enveloped delivery vehicles.
Jennifer Hamilton,Evelyn Chen,Barbara S. Perez,Cindy R. Sandoval Espinoza,Min Hyung Kang,Marena Trinidad,Wayne Ngo,Jennifer A. Doudna +7 more
TL;DR: It is shown that cell surface marker recognition by antibody fragments displayed on membrane-derived particles encapsulating CRISPR-Cas9 protein and guide RNA can deliver genome editing tools to specific cells.
70
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Connor A. Tsuchida,Nadav Brandes,Raymund Bueno,Marena Trinidad,Thomas Mazumder,Bingfei Yu,Byungjin Hwang,Christopher Chang,Jamin Liu,Yang Sun,Caitlin R. Hopkins,Kevin R. Parker,Yanyan Qi,Ansuman T. Satpathy,Edward A. Stadtmauer,Jamie H. D. Cate,Justin Eyquem,Joseph A. Fraietta,Carl H. June,Howard Y. Chang,Chun Ye,Jennifer A. Doudna +21 more
TL;DR: In this paper , a systematic analysis in primary human T cells was conducted, which revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the chromosome, including in pre-clinical chimeric antigen receptor T cells.
Decorating chromatin for enhanced genome editing using CRISPR-Cas9
Evelyn Chen,Enrique Lin-Shiao,Marena Trinidad,Mohammad Saffari Doost,David Colognori,Jennifer A. Doudna +5 more
TL;DR: A simple strategy to influence DNA repair pathway choice and improve HDR efficiency is described by engineering CRISPR-Cas9-methyltransferase fusion proteins to increase the observed HDR efficiency by three-fold and HDR:indel ratio by five-fold compared to that induced by unmodified Cas9.
27
Identifying therapeutic drug targets using bidirectional effect genes.
Karol Estrada,Steven Froelich,Arthur Wuster,Christopher R. Bauer,Teague Sterling,Wyatt T. Clark,Yuanbin Ru,Marena Trinidad,Hong Phuc Nguyen,Amanda R. Luu,Daniel J. Wendt,Gouri Yogalingam,Guoying Karen Yu,Jonathan H. LeBowitz,Lon R. Cardon +14 more
TL;DR: In this article, the authors proposed an approach to identify drug targets with high probability of success by focusing on genes with both gain of function (GoF) and loss of function mutations associated with opposing effects on phenotype (Bidirectional Effect Selected Targets, BEST).